biosimilar drugs
-
Senate Bill Proposes Slashing ‘Red Tape’ Around Biosimilar Interchangeability
Legislation introduced by Utah Senator Mike Lee would eliminate testing to show a biosimilar can be substituted for a reference biologic product. Lee contends the current testing requirement adds costs and delays market access for these lower-cost biological medicines.
-
Eli Lilly’s Insulin: Cheaper for Patients Without Much Financial Hit to the Firm
Eli Lilly is slashing prices for its insulin products and capping a patient’s monthly out-of-pocket costs at $35. But a financial analyst notes that the company can afford to cut prices on older medicines like insulin because the strategy will help it maintain pricing power for innovative new drugs.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Biocon expands portfolio & market reach with $3.3B buyout of Viatris biosimilars
Biocon Biologics is acquiring the biosimilars business of its longtime partner, Viatris. The deal gives Biocon a biosimilars presence in both emerging and developed markets, while Viatris sheds non-core assets as part of a broader strategic review.
-
Q&A: Biosimilars Forum engaged in education and advocacy as market is poised to take off
The Biosimilars Forum’s senior policy advisor, Michael Werner — who is also a partner at the law firm of Holland and Knight — talked with MedCity News about what’s going on with biosimilars.